298 related articles for article (PubMed ID: 22266819)
1. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.
Das K; Martinez SE; Bauman JD; Arnold E
Nat Struct Mol Biol; 2012 Jan; 19(2):253-9. PubMed ID: 22266819
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.
Hachiya A; Marchand B; Kirby KA; Michailidis E; Tu X; Palczewski K; Ong YT; Li Z; Griffin DT; Schuckmann MM; Tanuma J; Oka S; Singh K; Kodama EN; Sarafianos SG
J Biol Chem; 2012 Aug; 287(35):29988-99. PubMed ID: 22761416
[TBL] [Abstract][Full Text] [Related]
3. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.
Das K; Arnold E
Curr Opin Virol; 2013 Apr; 3(2):119-28. PubMed ID: 23602470
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
6. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Stammers DK
J Mol Biol; 2004 Feb; 336(3):569-78. PubMed ID: 15095972
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
[TBL] [Abstract][Full Text] [Related]
9. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.
Liu J; He X; Zhang JZ
J Mol Model; 2014 Oct; 20(10):2451. PubMed ID: 25234608
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
[TBL] [Abstract][Full Text] [Related]
11. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase.
Temiz NA; Bahar I
Proteins; 2002 Oct; 49(1):61-70. PubMed ID: 12211016
[TBL] [Abstract][Full Text] [Related]
13. Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage.
Das K; Martinez SE; Bandwar RP; Arnold E
Nucleic Acids Res; 2014 Jul; 42(12):8125-37. PubMed ID: 24880687
[TBL] [Abstract][Full Text] [Related]
14. Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.
Zheng X; Mueller GA; DeRose EF; London RE
Biophys J; 2013 Jun; 104(12):2695-705. PubMed ID: 23790378
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations.
Vijayan RS; Arnold E; Das K
Proteins; 2014 May; 82(5):815-29. PubMed ID: 24174331
[TBL] [Abstract][Full Text] [Related]
16. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
Xia Q; Radzio J; Anderson KS; Sluis-Cremer N
Protein Sci; 2007 Aug; 16(8):1728-37. PubMed ID: 17656585
[TBL] [Abstract][Full Text] [Related]
17. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
[TBL] [Abstract][Full Text] [Related]
18. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site.
Sarafianos SG; Das K; Ding J; Boyer PL; Hughes SH; Arnold E
Chem Biol; 1999 May; 6(5):R137-46. PubMed ID: 10322129
[TBL] [Abstract][Full Text] [Related]
19. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.
Biondi MJ; Beilhartz GL; McCormick S; Götte M
J Biol Chem; 2010 Aug; 285(35):26966-26975. PubMed ID: 20530477
[TBL] [Abstract][Full Text] [Related]
20. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
Sengupta D; Verma D; Naik PK
In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
